What is AOD-9604?
Compound Spotlight
AOD-9604 has an unusual distinction: it is one of the most thoroughly tested compounds in this entire category, and what that testing found was that it did not work for its intended purpose. It went the full distance through pharmaceutical development, failed its pivotal trial, and was discontinued. Understanding why is considerably more useful than the marketing version of this compound’s story.
Quick summary
- A 16-amino-acid synthetic peptide: the C-terminal lipolytic fragment of human growth hormone, plus an added N-terminal tyrosine.
- Designed to isolate hGH’s fat-metabolism effect from its growth, IGF-1, and blood-glucose effects — and that separation genuinely held up.
- Mechanism is β3-adrenergic receptor dependent, established by knockout-mouse pharmacology.
- Phase 2a (2001) showed roughly 1.8 kg above placebo over 12 weeks — real, but modest.
- Phase 2b (2007, 536 subjects) failed its primary efficacy endpoint. Obesity development was discontinued.
- Its lasting value is as a clean mechanistic tool and an unusually complete safety dataset, not as an effective weight-loss agent.
The design premise
Human growth hormone does several things at once. It promotes tissue growth and cell proliferation via IGF-1, it affects insulin sensitivity and blood glucose, and it stimulates lipolysis — the breakdown of stored fat. For anyone interested only in the last of those, the others are liabilities.
Researchers had mapped the lipolytic activity to the C-terminal region of the hGH molecule. Metabolic Pharmaceuticals, a spinout from Monash University in Melbourne, synthesized that fragment with an added tyrosine residue at the N-terminus and developed it as AOD-9604 — literally “Anti-Obesity Drug 9604.” The hypothesis was clean and testable: keep the fat-metabolism effect, discard everything else.
The mechanism holds up
The most-cited mechanistic evidence for AOD-9604 comes from β3-adrenergic receptor knockout mice. Wild-type mice given the compound showed significant increases in fat oxidation; β3-AR knockout mice given the same compound did not. Receptor-knockout pharmacology of this kind is the strongest available method for assigning a mechanism to a compound, and it establishes that AOD-9604’s lipolytic effect runs through β3-adrenergic signaling rather than through growth hormone receptors.
The separation from hGH’s other effects also held. Across human trials, AOD-9604 did not elevate IGF-1, did not impair glucose tolerance, and did not produce the edema, insulin resistance, or carpal tunnel symptoms associated with full growth hormone administration. On its own design terms, the molecule did what it was built to do.
What the human trials found
Phase 2a
The most frequently cited positive human result comes from a randomized, double-blind, placebo-controlled trial in obese adults over 12 weeks, with roughly 23 subjects per arm. Mean weight loss at the highest dose was approximately 2.6 kg versus 0.8 kg on placebo — about 1.8 kg of separation. Body composition analysis suggested the loss skewed toward fat mass rather than lean mass, consistent with the mechanistic hypothesis. Adverse effects were limited and mild.
That is a real signal. It is also a small, short trial, and 1.8 kg over three months is a marginal effect by the standards regulators apply to obesity drugs.
Phase 2b — the one that ended it
The OPTIONS study enrolled 536 subjects across multiple doses, running 24 weeks with a primary endpoint of weight loss at 12 weeks. It was adequately powered, properly controlled, and finished ahead of schedule.
It did not meet its primary efficacy endpoint. In February 2007, Metabolic Pharmaceuticals announced that the Phase 2b results did not support commercial viability for the obesity indication, and development for that indication was wound down. Detailed results were never published in a peer-reviewed journal, which is itself a limitation — the negative result is documented primarily through the sponsor’s regulatory disclosure rather than the scientific literature.
Why the Phase 2a and Phase 2b results diverged
This is a common and instructive pattern in drug development. Small early trials are more vulnerable to chance findings, and a modest true effect can appear larger than it is in a study with roughly 23 people per arm. When the same compound is tested in 536 people, the estimate regresses toward the truth. The most parsimonious reading is not that AOD-9604 does nothing, but that its real effect size is small enough to disappear into the noise at scale — which, for a therapeutic candidate, amounts to the same verdict.
It is worth noting that the compound’s animal data were strong. Rodent obesity models are well documented to be poor predictors of human efficacy, and AOD-9604 is a textbook case of that gap.
Where it stands now
AOD-9604 is not approved for any indication in any major jurisdiction. In the United States the FDA has listed it as a bulk drug substance that may present safety risks for compounding purposes. It has been examined for other directions since the obesity program ended, including cartilage and osteoarthritis research, where the rationale shifts to chondrocyte effects rather than lipolysis.
Its genuine ongoing research value is twofold: it is a selective tool for studying β3-adrenergic-mediated lipolysis without the IGF-1 confound that full growth hormone introduces, and it carries an unusually complete human safety dataset for a compound of this type — precisely because it was tested properly and reported honestly.
Frequently asked questions
Is AOD-9604 the same as HGH Fragment 176-191?
They are closely related but not identical. AOD-9604 is the fragment with an added N-terminal tyrosine residue, a modification made during pharmaceutical development. The two are frequently conflated in commercial listings.
If it failed its trial, why is it still discussed?
Because a failed efficacy endpoint is not the same as a failed mechanism. The β3-adrenergic lipolytic mechanism is well established and the safety profile is clean. What the trial showed is that the effect is too small to be clinically meaningful for obesity treatment — which is useful information, not a reason to pretend the trial did not happen.
Does it raise IGF-1 like growth hormone does?
No. Across the published human trials it did not elevate IGF-1 or affect glucose tolerance. This separation was the central design goal and it is one of the better-supported findings about the compound.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.
References
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001.
- Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab.
- Metabolic Pharmaceuticals. ASX announcement: Phase 2B results for AOD9604 do not support commercial viability (obesity indication). 21 February 2007.
- Cox HD, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(9):808–814.
View the AOD-9604 product listing →
Read our growth hormone secretagogue guide →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. AOD-9604 is not approved by any regulatory authority and did not meet its primary efficacy endpoint in Phase 2b trials. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
